Risk of wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm

Cancer Epidemiology

Volumn 39, Issue 2, 2015, Pages 242-249

  Wu, Jasmanda ^a   Zhang, Ling ^a   Vaze, Anjali ^a   Lin, Stephen ^a   Juhaeri, Juhaeri ^a  

^a SANOFI   (France)

Author keywords

Cardiac disorders; Myelofibrosis; Myeloproliferative neoplasm; Wernicke's encephalopathy

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART ARRHYTHMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; WERNICKE ENCEPHALOPATHY; CARDIOVASCULAR DISEASES; COMPLICATION; MYELOPROLIFERATIVE DISORDERS; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS; WERNICKE ENCEPHALOPATHY;

EID: 84926210446     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.01.014     Document Type: Article

References (24)

1. Vardiman J.W., Thiele J., Arber D.A., Burnning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
2. Tefferi A., Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011, 29:573-582.
3. Kutti J., Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 2001, 49:164-166.
4. Campbell P.J., Green A.R. Management of polycythemia vera and essential thrombocythemia. Hematology (Am Soc Hematol Educ Program) 2005, 20:1-208.
5. Deschler B., Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006, 107:2099-2107.
6. Phekoo K.J., Richards M.A., Moller H., Schey S.A. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006, 91:1400-1404.
7. Smith A., Howell D., Patmore R., Jack A., Roman E. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer 2011, 105:1684-1692.
8. Tefferi A., Huang J., Schwager S., Li C.Y., Wu W., Pardanani A., et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007, 109(10):2083-2088.
9. Barbui T., Carobbio A., Cervantes F., Vannucchi A.M., Guglielmelli P., Antonioli E., et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010, 115:778-782.
10. Passamonti F., Rumi E., Arcaini L., Boveri E., Elena C., Pietra D., et al. Prognositic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008, 93:1645-1651.
11. Carobbio A., Finazzi G., Antoniolli E., Guglielmelli P., Vannucchi A.M., Delaini F., et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008, 112:3135-3137.
12. Marchioli R., Finazzi G., Landolfi R., Kutti J., Heinz G., Carlo P., et al. Vascular and neoplastic risk in a large cohort patients with polychthemia vera. J Clin Oncol 2005, 23:2224-2232.
13. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med 2013, 369:2391-2405.
14. Rotunno G., Mannarelli C., Gulielmelli P., Pacilli A., Pancrazzi A., Pieri L., et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014, 123:1552-1555.
15. GianPietro S., Alessandro S. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007, 6:442-455.
16. Kuo S.H., Debnam J.M., Fuller G.N., de Groot J. Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. Oncology 2009, 76:10-18.
17. De Reuck J., Sieben G., De Coster W., Vander Eecken H. Prospective neuropathologic study on the occurrence of Wernicke's encephalopathy in patients with tumors of the lymphoid-hemopoietic systems. Acta Neuropathol 1981, (Suppl. VII):356-358.
18. Health Insurance Portability and Accountability Act of 1996. 42 USC 1320-d2.
19. Rolland S., Truswell A.S. Wernicke-Korsakoff syndrome in Sydney hospitals after 6 years of thiamin enrichment of bread. Public Health Nutr 1998, 1(2):117-122.
20. Mini-Sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data - congestive heart failure. Accessed 14.04.14. http://www.mini-sentinel.org/work_products/HealthOutcomes/MS_HOI_CHFReport.pdf.
21. Mini-Sentinel systematic validation of health outcome of interest - acute myocardial infarction cases report. Accessed 14.04.14. http://www.mini-sentinel.org/work_products/Validation_HealthOutcomes/Mini-Sentinel-Validation-of-AMI-Cases.pdf.
22. Mini-Sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data - cardiac arrhythmias report. Accessed 14.04.14. http://www.mini-sentinel.org/work_products/HealthOutcomes/MS_HOI_CardiacArrhythmiasReport.pdf.
23. Quan H., Sundararajan V., Halfon P., Fong A., Burnand B., Luthi J.C., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43:1130-1139.
24. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.